Dermata Therapeutics(DRMA) - 2024 Q1 - Quarterly Results

EX-99.1 2 drma_ex991.htm PRESS RELEASE "We are very encouraged by the enrollment numbers to date of our STAR-1 clinical trial in acne and we are on track to complete enrollment by the end of 2024," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "With very few competing Phase 3 acne studies, we are confident in our team's ability to get our STAR-1 study fully enrolled this year, with topline data expected in the first quarter of 2025. If positive, we believe this would pu ...